摩贝首页> 化合物百科> 其他> 化学试剂> 含氮有机物> 环孢菌素

环孢菌素

英文名称:cyclosporin A

化学药物 激素及有关药物 抗肿瘤类药物 兽用化学药品
CAS : 59865-13-3 精确质量 : 1201.84000
分子式 : C62H111N11O12 logP : 4.14950
分子量 : 1202.61000 PSA : 278.80000

基本信息

纠错
中文名称:
环孢菌素
中文别名:

环孢霉素A;

环胞霉素A;

英文名称:
cyclosporin A
英文别名:

s7481f1;

Neoral;

Atopica;

sandimmun neoral;

ciclosporin A;

查看更多英文别名

CAS号:
59865-13-3
分子式:
C62H111N11O12
分子量:
1202.61000
精确质量:
1201.84000
PSA:
278.80000
LogP:
4.14950

物化性质

纠错
外观与性状:
从-15℃的丙酮得白色针状结晶,熔点148~151℃,[α]D20-244°(C=0.6,氯仿)。溶于甲醇、乙醇、丙酮、乙醚或氯仿,微溶于水及饱和碳氢化合物。急性毒性LD50小鼠,大鼠,兔子(mg/kg):107,25,>10静脉注射;2329,1480,>1000口服。
密度:
1.016 g/cm3
熔点:
148-151°C
沸点:
1293.8ºC at 760 mmHg
储存条件:
2-8°C

安全信息

纠错
  • 海关编码:2941909000
  • WGK Germany:3
  • 危险类别码:R45; R60; R22
  • 安全说明:53-45-36/37-24/25-22
  • RTECS号:GZ4120000
  • 危险品标志:T

生产方法及用途

查看全部

生产方法

1.以多孢木霉菌(Tolypocladium inflatum Cams)为生产菌株。75L罐内装50L种子培养基,接种5×109个孢子,Ph=5.4—4.3,培养72h,得到一级种子液。750L发酵罐内装500L发酵培养基,种入上述一级种子液,培养6天,得二级种子液。4500L发酵罐内装3000L发酵培养基,发酵12天,得到环孢素发酵毒。往发酵液中加人等体积的乙酸乙酯提取,分出有机层,减压蒸发,得粗品。融化处理,可得环孢素和环孢菌素C组分,其中环孢素的产量约为150~200mg/L环孢菌素C约为50~100mg/L。
2.以多孢木霉菌为生产菌株。先制备环孢素发酵液。向发酵液中加入乙酸乙酯提取,分出有机层,减压蒸发,得粗品。经纯化处理可得。

用途

优级纯。

上下游产品

上游产品总计:0下游产品总计:2
下游产品 总计:2 查看更多
  • MSDS
纠错
  Cyclosporin A      Revision number: 5    
  SAFETY DATA SHEET

Section 1. IDENTIFICATION
  Product name:        Cyclosporin A    
    
  Revision number:        5    

Section 2. HAZARDS IDENTIFICATION
  GHS classification
  PHYSICAL HAZARDS        Not classified    
  HEALTH HAZARDS
  Acute toxicity (Oral)        Category 4    
    Category 1A
  Carcinogenicity
  Reproductive toxicity        Category 1B    
  Reproductive toxicity (Effects on or via lactation) Additional category for effects on or via lactation
  ENVIRONMENTAL HAZARDS        Not classified    
  GHS label elements, including precautionary statements
  Pictograms or hazard symbols
  Signal word        Danger    
  Hazard statements        Harmful if swallowed    
    May cause cancer
    May damage fertility or the unborn child
    May cause harm to breast-fed children
  Precautionary statements:
    Obtain special instructions before use.
  [Prevention]
    Do not handle until all safety precautions have been read and understood.
    Do not breathe dust/fume/gas/mist/vapours/spray.
    Avoid contact during pregnancy/while nursing.
    Do not eat, drink or smoke when using this product.
    Wash hands thoroughly after handling.
    Use personal protective equipment as required.
  [Response]        IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell.    
    Rinse mouth.
    IF exposed or concerned: Get medical advice/attention.
  [Storage]        Store locked up.    
  [Disposal]        Dispose of contents/container through a waste management company authorized by    
    the local government.

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
    Substance
  Substance/mixture:
  Cyclosporin A

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
  Components:        Cyclosporin A    
  Percent:        >97.0%(LC)(N)    
  CAS Number:        59865-13-3    
  Synonyms:        Cyclosporin    
  Chemical Formula:        C62H111N11O12    

Section 4. FIRST AID MEASURES
  Inhalation:        Remove victim to fresh air and keep at rest in a position comfortable for breathing.    
    Get medical advice/attention.
  Skin contact:        Remove/Take off immediately all contaminated clothing. Gently wash with plenty of    
    soap and water. Get medical advice/attention.
  Eye contact:        Rinse cautiously with water for several minutes. Remove contact lenses, if present    
    and easy to do. Get medical advice/attention.
  Ingestion:        Get medical advice/attention.Rinse mouth.    
  Protection of first-aiders:        A rescuer should wear personal protective equipment, such as rubber gloves and air-    
    tight goggles.

Section 5. FIRE-FIGHTING MEASURES
  Suitable extinguishing        Dry chemical, foam, water spray, carbon dioxide.    
  media:
  Specific hazards arising Take care as it may decompose upon combustion or in high temperatures to
  from the chemical:        generate poisonous fume.    
  Precautions for firefighters: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
    method according to the surrounding situation is used. Uninvolved persons should
    evacuate to a safe place. In case of fire in the surroundings: Remove movable
    containers if safe to do so.
  Special protective        When extinguishing fire, be sure to wear personal protective equipment.    
  equipment for firefighters:

Section 6. ACCIDENTAL RELEASE MEASURES
    Use extra personal protective equipment (P3 filter respirator for toxic particles). Keep
  Personal precautions,
  protective equipment and people away from and upwind of spill/leak. Entry to non-involved personnel should
  emergency procedures: be controlled around the leakage area by roping off, etc.
  Environmental precautions: Prevent product from entering drains.
  Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
  containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
  up: appropriate laws and regulations.

Section 7. HANDLING AND STORAGE
  Precautions for safe handling
  Technical measures:        Handling is performed in a well ventilated place. Wear suitable protective equipment.    
    Prevent dispersion of dust. Wash hands and face thoroughly after handling.
    Use a closed system if possible. Use a local exhaust if dust or aerosol will be
    generated.
  Advice on safe handling: Avoid all contact!
  Conditions for safe storage, including any
  incompatibilities
  Storage conditions:        Keep container tightly closed. Store in a refrigerator.    
    Store locked up.
    Store away from incompatible materials such as oxidizing agents.
    Heat-sensitive
    Comply with laws.
  Packaging material:

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
  Engineering controls:        Install a closed system or local exhaust. Also install safety shower and eye bath.    
  Cyclosporin A

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
  Personal protective equipment
  Respiratory protection: Dust respirator, self-contained breathing apparatus(SCBA), supplied air respirator,
    etc. Use respirators approved under appropriate government standards and follow
    local and national regulations.
  Hand protection:        Impervious gloves.    
    Safety goggles. A face-shield, if the situation requires.
  Eye protection:
  Skin and body protection: Impervious protective clothing. Protective boots, if the situation requires.

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
  Physical state (20°C):        Solid    
    Crystal- Powder
  Form:
  Colour:        White - Almost white    
    No data available
  Odour:
  pH: No data available
  Melting point/freezing point:151°C
  Boiling point/range:        No data available    
  Flash point:        No data available    
  Flammability or explosive
  limits:
  Lower:        No data available    
  Upper:        No data available    
  Relative density:        No data available    
  Solubility(ies):
  [Water]        No data available    
  [Other solvents]
  Very soluble:        Methanol, Ether, Acetone, Ethanol    
  Soluble:        Chloroform    
  Log Pow:        2.92    

Section 10. STABILITY AND REACTIVITY
  Chemical stability:        Stable under proper conditions.    
  Possibility of hazardous No special reactivity has been reported.
  reactions:
  Incompatible materials: Oxidizing agents
  Hazardous decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx)
  products:

Section 11. TOXICOLOGICAL INFORMATION
  Acute Toxicity:        orl-rat LD50:1480 mg/kg    
    ipr-rat LD50:147 mg/kg
    scu-rat LD50:286 mg/kg
    ivn-rat LD50:24 mg/kg
  Skin corrosion/irritation: No data available
  Serious eye        No data available    
  damage/irritation:
  Germ cell mutagenicity: sce-hmn-lym 1 mg/L
    oms-hmn-lym 50 mg/L
  Carcinogenicity:        orl-man TDLo:259 mg/kg/2W-C    
  IARC =        Group 1 (Carcinogenic to humans)    
  NTP =        a (Known to be carcinogens)    
    No data available
  Reproductive toxicity:
  RTECS Number:        GZ4120000    

Section 12. ECOLOGICAL INFORMATION
  Ecotoxicity:
  Fish:        No data available    
  Crustacea:        No data available    
  Cyclosporin A

Section 12. ECOLOGICAL INFORMATION
  Algae:        No data available    
  Persistence / degradability: No data available
  Bioaccumulative        No data available    
  potential(BCF):
  Mobility in soil
    2.92
  Log Pow:
  Soil adsorption (Koc):        No data available    
    No data available
  Henry's Law
  constant(PaM3/mol):

Section 13. DISPOSAL CONSIDERATIONS
    Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
    with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
    Observe all federal, state and local regulations when disposing of the substance.

Section 14. TRANSPORT INFORMATION
    Does not correspond to the classification standard of the United Nations
  Hazards Class:
  UN-No:        Not listed    

Section 15. REGULATORY INFORMATION
  Safe management ordinance of dangerous chemical product (State Council announces on January 26, 2002
  and revised on February 16,2011): Safe use and production, the storage of a dangerous chemical, transport,
    loading and unloading were prescribed.


SECTION 16 - ADDITIONAL INFORMATION
N/A

海关数据

查看详细

中国海关编码:

2941909000

毒性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GZ4120000
CHEMICAL NAME :
Cyclosporin A
CAS REGISTRY NUMBER :
59865-13-3
LAST UPDATED :
199801
DATA ITEMS CITED :
35
MOLECULAR FORMULA :
C62-H111-N11-O12
MOLECULAR WEIGHT :
1202.84

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1911 mg/kg/91W-I
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Behavioral - coma Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
62500 ug/kg/5D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes Nutritional and Gross Metabolic - body temperature increase
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
20 mg/kg/2D-I
TOXIC EFFECTS :
Behavioral - headache Vascular - acute arterial occlusion Lungs, Thorax, or Respiration - cyanosis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human
DOSE/DURATION :
12 mg/kg
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section Endocrine - antidiuresis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
30 mg/kg/4D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1480 mg/kg
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
147 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
286 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
24 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
2329 mg/kg
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
96 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
>1 gm/kg
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity Gastrointestinal - hypermotility, diarrhea Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
10 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
140 mg/kg/14D-I
TOXIC EFFECTS :
Endocrine - changes in spleen weight Blood - changes in spleen
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
350 mg/kg/7D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - multiple enzyme effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
800 mg/kg/10D-I
TOXIC EFFECTS :
Behavioral - food intake (animal) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
420 mg/kg/28D-I
TOXIC EFFECTS :
Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Musculoskeletal - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
700 mg/kg/28D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Kidney, Ureter, Bladder - other changes in urine composition
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
210 mg/kg/14D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - renal function tests depressed Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other transferases
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1200 mg/kg/40D-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Metabolism (Intermediary) - amino acids (including renal excretion) Biochemical - Metabolism (Intermediary) - Plasma proteins not involving coagulation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
140 mg/kg/7D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section Vascular - regional or general arteriolar or venous dilation
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
60 mg/kg/3D-I
TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section Vascular - structural changes in vessels Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
259 mg/kg/2W-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - lymphoma, including Hodgkin's disease
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
166 mg/kg
SEX/DURATION :
male 45 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - other effects on male Reproductive - Fertility - male fertility index (e.g. # males impregnating females per # males exposed to fertile nonpregnant females)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
420 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
560 mg/kg
SEX/DURATION :
male 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count) Reproductive - Paternal Effects - testes, epididymis, sperm duct Reproductive - Paternal Effects - other effects on male
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
90 mg/kg
SEX/DURATION :
female 6-8 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
50 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
210 mg/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - ovaries, fallopian tubes Reproductive - Fertility - other measures of fertility

MUTATION DATA

TYPE OF TEST :
Sister chromatid exchange
TEST SYSTEM :
Human Lymphocyte
DOSE/DURATION :
1 mg/L
REFERENCE :
IGAYAY Igaku No Ayumi. Progress in Medicine. (Ishiyaku Shuppan K.K., 1-7-10, Honkomagom, Bunkyo-ku, Tokyo, Japan) V.1- 1946- Volume(issue)/page/year: 134,403,1985 *** REVIEWS *** IARC Cancer Review:Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,77,1990 IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,77,1990 IARC Cancer Review:Group 1 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 50,77,1990

共有5种不同规格的现货商品

最低¥1100.00

立即前往商城

共有43种不同规格的现货商品

最低¥73.00

立即前往商城

共有6种不同规格的现货商品

最低¥1100.00

立即前往商城

摩贝商城为您提供

共有43种不同规格的现货商品

最低¥73.00

立即前往商城

其它您可能感兴趣的化合物

快捷导航
醇类 有机硅 有机磷 含氮有机物 无机化合物 杂环化合物 卤化物 手性化合物 羰基化合物 硼酸衍生物 芳香化合物 烯烃类 含硫有机物 呼吸系统药物 皮肤病药物 中枢神经系统药物 水、电解质及酸碱平衡调节药物 外用消毒及防腐类药物 维生素、氨基酸及辅酶类 维生素、矿物质 五官科药物 消化系统药物 消炎药物 血液(造血系统)类药物 循环(心血管)系统药物 影响免疫功能药物 诊断用药物 中枢中枢神经系统药物 注射用药物 免疫调节剂 泌尿系统与生殖药物 麻醉用药物 化学药物 激素及有关药物 解热镇痛药物 抗变态反应(过敏)及各类解毒药物 抗病毒药物 抗感染药物 抗寄生虫及抗螺旋体药物 抗结核病药物 抗麻风病药物 抗疟疾药物 抗生素类药物 抗微生物药物 抗真菌药物 抗肿瘤类药物 喹诺酮类药物 专科用药物 兽医诊断制品 兽用化学药品 兽用消毒剂 预防用兽用生物制品 治疗用兽用生物制品 中兽药、天然药物 生物化学品 药用辅料 原料药 医药中间体 兽药
词典热推
碳酸二(2-吡啶)酯 2-溴-4-氯-6-硝基苯胺 5-氨基乙酰丙酸盐酸盐 2,6-吡啶二羰酰氯 N-(4-氯-2-硝基苯基)乙酰胺 N-羟基-N'-3-吡啶基辛二酰胺 (R)-1-叔丁氧羰基-3-(氨基甲基)吡咯烷 N-三羟甲基甲基丙烯酰胺 达西司特 N-(4-氯苯基)-环己基甲酰胺
厂家库
二氢环孢菌素A厂家 6-[(3R,4R)-3-(乙酰氧基)-N,4-二甲基-6-氧代-L-正亮氨酸]环孢菌素A厂家

化工圈APP

二维码

微信公众号

二维码